Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/170029
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Olivan Riera, Mireia | - |
dc.contributor.author | Rigau, Marina | - |
dc.contributor.author | Colás, Eva | - |
dc.contributor.author | Garcia, Marta | - |
dc.contributor.author | Montes, Melania | - |
dc.contributor.author | Sequeiro, Tamara | - |
dc.contributor.author | Regis, L. | - |
dc.contributor.author | Celma, Anna | - |
dc.contributor.author | Planas, Jacques | - |
dc.contributor.author | Reventós Puigjaner, Jaume | - |
dc.contributor.author | Torres, Inés de | - |
dc.contributor.author | Doll, Andreas | - |
dc.contributor.author | Morote, Juan | - |
dc.date.accessioned | 2020-08-28T11:49:35Z | - |
dc.date.available | 2020-08-28T11:49:35Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.uri | http://hdl.handle.net/2445/170029 | - |
dc.description.abstract | Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these treatments were evaluated by proliferation, colony formation, invasion, and migration assays using different PCa cell lines, in order to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95% CI: 0.467-0.812), ). However, if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068-3.155), ) or the combination of both drugs (OR: 3.059 (95% CI: 1.894-4.939), ) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with statins and aspirin has a protective effect on PCa incidence. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Hindawi | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1155/2015/762178 | - |
dc.relation.ispartof | BioMed Research International, 2015, vol. 2015, p. 762178 | - |
dc.relation.uri | https://doi.org/10.1155/2015/762178 | - |
dc.rights | cc-by (c) Olivan Riera, Mireia et al., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Aspirina | - |
dc.subject.classification | Càncer de pròstata | - |
dc.subject.classification | Tractament adjuvant del càncer | - |
dc.subject.other | Aspirin | - |
dc.subject.other | Prostate cancer | - |
dc.subject.other | Adjuvant treatment of cancer | - |
dc.title | Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 700405 | - |
dc.date.updated | 2020-08-27T16:04:54Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25649906 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
700405.pdf | 2.77 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License